CLB
Core Laboratories NV
10.90$
+0.0%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +2.3% | +1.1% | +0.7% | +2.9% | -3.8% | -4.4% | +5.3% | +3.4% | +2.8% | -11.9% | +2.3% | – | |
| – | +1.0% | +6.8% | -1.6% | +3.5% | -0.6% | -6.1% | +4.1% | +1.0% | +4.3% | -9.8% | -0.7% | – | |
| – | +7.6% | -20.6% | +12.6% | +0.2% | -19.0% | +5.3% | +11.7% | +14.2% | -3.7% | -21.3% | +17.8% | – | |
| – | -8.3% | +32.7% | -10.8% | -18.8% | +9.0% | +50.3% | -23.3% | +2.1% | -11.8% | +56.1% | -25.6% | – | |
| – | +19.6% | +4.3% | -37.7% | -47.7% | +26.4% | +207.3% | -53.1% | -32.0% | +76.5% | +98.3% | -21.0% | – | |
| – | -0.6% | -41.2% | +86.8% | +23.7% | -28.4% | -68.8% | +246.2% | +36.9% | -23.2% | -88.3% | +384.9% | – | |
| – | +15.0% | -5.4% | -6.3% | -3.1% | -15.4% | -1.0% | +4.2% | -2.3% | -1.5% | +10.8% | -1.6% | – | |
| – | -4.9% | -53.0% | +148.6% | +30.4% | -30.8% | -84.3% | +593.1% | +45.3% | -27.7% | -107.6% | – | – | |
| – | +270.0% | -80.6% | +117.7% | +30.0% | -13.1% | -57.2% | +9.5% | +96.4% | +115.6% | -103.1% | – | – | |
| – | -76.2% | +46.4% | +180.5% | +30.0% | -37.0% | -102.1% | – | +33.9% | -65.3% | -115.9% | – | – | |
| – | +0.9% | -33.9% | +59.3% | +18.7% | -24.0% | -54.4% | +178.8% | +8.1% | -20.5% | -71.0% | +129.6% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.